DAIICHI SANKYO, INC.

Alteogen signed an exclusive license agreement with Daiichi Sankyo to develop and commercialize a subcutaneous version of Enhertu, an ADC cancer treatment, using Alteogen’s ALT-B4 technology. Daiichi Sankyo will pay $20 million upfront and up to $280 million in additional payments based on milestones, with royalties on net sales. This marks the first global attempt to convert ADCs into subcutaneous formulations, potentially reducing side effects and improving efficacy.

Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.

FDA approves Caris Life Sciences' MI Cancer Seek as companion diagnostic for multiple cancer drugs across six cancer types, including solid tumours, breast cancer, colorectal cancer, melanoma, non-small cell lung cancer, and endometrial carcinoma. The assay uses whole exome sequencing (WES) and whole transcriptome sequencing (WTS) for molecular profiling of solid tumours.

Tendinopathy market poised for growth due to increasing prevalence, awareness, and emerging treatments by companies like MiMedx, Novartis, Ipsen, and others. Key therapies include secukinumab, PRP, MSCs, corticosteroids, nitroglycerin patches, BPC-157, collagen hydrolysate, and hyaluronic acid. Market drivers include aging populations, sports participation, biologics advancements, and early diagnosis. Barriers include high therapy costs, limited awareness in developing countries, lack of standardized protocols, and competing therapies.

Valemetostat, a dual EZH1/EZH2 inhibitor, showed activity in relapsed/refractory peripheral T-cell lymphoma (PTCL) patients, with 44% objective response and manageable safety profile, in a phase II trial (VALENTINE-PTCL01).

First patients dosed in 3 phase 3 trials of Dato-DXd combinations for advanced NSCLC: TROPION-Lung10 (Dato-DXd + rilvegostomig vs pembrolizumab), TROPION-Lung14 (Dato-DXd + osimertinib vs osimertinib), and TROPION-Lung15 (Dato-DXd +/− osimertinib vs chemotherapy).

Allen B. Reitz, Ph.D., CEO of Fox Chase Therapeutics Discovery Inc., receives the second annual Timothy M. Block, PhD, Biotech Impact Award at the 24th Annual Regional Biotechnology Conference. The event, sponsored by Daiichi Sankyo, supports research at the Hepatitis B Foundation and Blumberg Institute. Dr. Reitz is recognized for his professional achievements in drug discovery and community leadership.

Cancer has become more manageable due to tailored treatments, with leaders in oncology pushing for genetic insights and data research. This year's Cancer Care Visionaries include Dr. Hesham Abdullah, Jason Bock, Arnon Chait, Raffaele Colombo, Dr. Yusri Elsayed, Mark Erlander, Dr. Marjorie Green, Raquel Izumi, Dr. Biljana Naumovic, Dr. Amita Patnaik, Dr. Mary Pinder-Schenck, Amoolya Singh, and AmirAli Talasaz, each contributing unique perspectives on cancer therapy and leadership.

The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.